ZBIO
Zenas BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.46
+0.28%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$29.27
From 52W high−34.07%
Volume800703.00
Market cap$1.85B
P/E (TTM)—
P/S (TTM)1854.9x
Div yield—
Key dataNov 4, 2026
Open
$29.27
From 52W high
−34.07%
Volume
800703.00
Market cap
$1.85B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.5x
P/E (TTM)
—
RSI (14)
52.7
MomentumView details →
1D Return
+0.28%
YTD Return
−21.56%
SummaryUpdated Jun 1, 2026
Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Waltham, Massachusetts. The company went public in September 2024 through an initial public offering. Zenas focuses on developing transformative immunology-based therapies for autoimmune and inflammatory diseases, with its lead product candidate obexelimab currently in clinical trials for multiple indications including rare autoimmune conditions and multiple sclerosis.
Similar companies
Latest newsMore news →